CSPC reports 18.5% revenue decline, maintains dividend

CSPC Pharmaceutical Group reported revenue fell 18.5% to RMB13,273 million and profit dropped 15.6% to RMB2,548 million for the first half of 2025.

The company declared an interim dividend of HK$0.14 per share and repurchased 64.3 million shares for approximately HK$300 million. Finished drug sales declined 24.4% while bulk products increased 11.9%.